The time it takes to see results may vary from person to person
If only we could encourage the body to make more cAMP and prevent phophodietrase from breaking it down
Key questions remain unanswered in ARD patients, particularly whether disease-specific factors (altered inflammation, gut microbiome) or ARD treatments (e.g., glucocorticoids, TNF or IL-6 inhibitors) may modify the immunomodulatory effects of GLP-1RAs
Lotte Bjerre Knudsen, the legendary Chief Scientific Advisor at Novo Nordisk and the driving force behind the development of semaglutide (recently recognized with the 2025 Breakthrough Prize), took the stage
"If you are increasing the protein, you're decreasing the rapidly absorbable carbohydrates, you're decreasing fat, excess calories, and sugar," says Kessler
Exenatide enhanced the antitumor efficacy on PD-1 blockade by the attenuation of neutrophil extracellular traps